🔺 What to do when markets are at an all-time high? Find smart bargains, like these.See Undervalued Shares

Nestle cuts full-year outlook after sales miss

Published 16/10/2015, 08:10
© Reuters. Sample products are on display at Nestle headquarters in Vevey
BARC
-
NESN
-
DANO
-
ULVR
-
UNc
-

By Brenna Hughes Neghaiwi

VEVEY, Switzerland (Reuters) - Nestle (VX:NESN), the world's largest packaged food company, lowered its full-year outlook on Friday, as a Maggi noodle recall in India knocked sales and undercalculated U.S. Skin Health rebates weighed on the Swiss company's profits.

Sales dropped 2.1 percent to 64.9 billion Swiss francs (44 billion pounds) in the nine months through September, missing analysts' average forecast of 65.9 billion in a Reuters poll.

Organic or underlying growth, adjusted for currency swings, acquisitions and divestitures, slowed to 4.2 percent in the period from 4.5 percent in the first half, sliding further behind its 5 percent target for 2015.

The company cut its 2015 outlook to around 4.5 percent, below its long-term model calling for 5 to 6 percent growth.

"The shortfall comes from pricing, as Nestle does not seem to have been able to pursue its pricing actions as hoped, and more importantly the issue seems to be again the Asia, Oceania, Australia region, with sales down in the third quarter," Barclays (L:BARC) analysts wrote in a note.

Chief Executive Paul Bulcke said: "After a good performance in the first half of the year, we were impacted in the third quarter by exceptional events, with Maggi noodles in India and a rebate adjustment in Nestle Skin Health."

Maggi noodles were subject to a recall in India over safety concerns.

In the United States, frozen food sales began improving after a revamp of Nestle's Lean Cuisine brand, but this contrasted with lagging sales in China, which showed a slower sales recovery, Bulcke said.

SIGNIFICANT IMPACT

India's Maggi noodle recall continued to have a significant impact on growth in the South Asia Region, Nestle said.

In its Skin Health division, Nestle's U.S. prescription drug rebates exceeded what it had set aside for this purpose, resulting in an additional one-off charge in the third quarter.

Despite prospects that Europe's hot summer would have consumers grabbing ice cream out of freezers, sales at the group's milk products and ice cream unit fell 350 million francs year-on-year to 11 billion. Water, however, achieved 7.1 organic growth through September, second only to confectionery at 7.8 percent.

Nestle earlier this month confirmed it was in advanced talks to merge its international ice cream business with R&R Ice Cream, in its latest effort to refocus on other, higher-performing brands and advance its goal of becoming a "nutrition, health and wellness" company.

Unilever (L:ULVR) (AS:UNc), the global number one in ice cream, on Thursday posted third-quarter underlying sales up 5.7 percent, thanks in part to a strong summer. But the Anglo-Dutch group said it expected sluggish global markets to keep weighing on performance.

© Reuters. Sample products are on display at Nestle headquarters in Vevey

Nestle stock trades at around 21.4 times 12-month forward earnings, above Danone (PA:DANO) and Unilever, according to StarMine, which weights analysts' estimates by their track record.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.